Defining the p53 DNA-binding domain/Bcl-xL-binding interface using NMR  by Petros, Andrew M et al.
De¢ning the p53 DNA-binding domain/Bcl-xL-binding interface using
NMR
Andrew M. Petros, Angelo Gunasekera, Nan Xu, Edward T. Olejniczak, Stephen W. Fesik
Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Rd., R46Y, AP10, Abbott Park, IL 60064, USA
Received 21 November 2003; revised 22 December 2003; accepted 8 January 2004
First published online 27 January 2004
Edited by Varda Rotter
Abstract p53 exerts its tumor suppressor activity through both
transcription-dependent and transcription-independent process-
es. Although the transcription-dependent activity of p53 has
been extensively studied, the mechanism for transcription-inde-
pendent p53-mediated tumor suppression is less well known.
Recently, it was reported that p53 can directly induce mitochon-
drial permeabilization and promote apoptosis. This occurs
through complexation of the DNA-binding region of p53 with
the anti-apoptotic proteins Bcl-xL and Bcl-2 (Mihara, M. et al.
(2003) Mol. Cell 11, 577^590). Using nuclear magnetic reso-
nance (NMR) spectroscopy we show that the interaction surface
on p53 involves the same region that is used by the protein to
contact DNA. The p53-binding site on Bcl-xL consists of the
carboxy-terminus of the ¢rst K-helix, the loop between K3 and
K4, and the loop between K5 and K6 of Bcl-xL. Furthermore,
the interaction of p53 with Bcl-xL is blocked by the binding of a
25-residue peptide derived from the BH3 region of the pro-ap-
optotic protein referred to as Bad.
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1. Introduction
The tumor suppressor protein p53 can trigger growth arrest
or apoptosis in response to oncogenic stress such as DNA
damage or hypoxia [1]. One way in which it acts is as a tran-
scription factor, to either activate or suppress certain genes.
However, several studies have suggested that the ability of p53
to induce apoptosis may not be solely dependent on its tran-
scriptional role. For instance, several p53 mutants have been
identi¢ed that are unable to regulate gene expression yet still
retain the ability to induce apoptosis [2]. Furthermore, it has
been shown that p53 can localize to the mitochondria and
interact with anti-apoptotic Bcl-2 family members [2]. The
Bcl-2 family of proteins, which are important regulators of
apoptosis, modulate mitochondrial membrane integrity, at
least in part, through heterodimerization of pro- and anti-ap-
optotic members. Mutants of p53 such as P72R, which local-
ize to the mitochondrial membrane more than the wild-type
protein, have an enhanced apoptotic potential [3]. The exact
mechanism for p53-mediated apoptosis is still not clear, how-
ever, an interaction between p53 and Bcl-xL or Bcl-2 could
free pro-apoptotic Bax or Bak and thus induce changes in the
mitochondrial membrane leading to the activation of the cas-
pase cascade resulting in cell death.
We have investigated the protein^protein interaction be-
tween the DNA-binding domain of p53 and Bcl-xL using nu-
clear magnetic resonance (NMR) spectroscopy. Complexation
results in residue-speci¢c spectral changes which de¢ne the
points of contact between the two proteins. In addition, we
have investigated the e¡ect on complex formation of BH3
peptide binding to Bcl-xL. These results are compared to a
recently proposed model for the interaction surface of these
two proteins and to known mutations of p53.
2. Materials and methods
2.1. Sample preparation
Bcl-xL was expressed in Escherichia coli and puri¢ed as previously
described [4]. A loop-deleted form of the protein was employed in
which the long unstructured loop connecting K1 to K2 was truncated
[4]. The anti-apoptotic potential of this protein is equivalent to the
wild-type [4]. A uniformly 15N,13C-labelled sample was prepared with
a minimal medium containing 15NH4Cl as the sole nitrogen source
and [U-13C]glucose as the sole carbon source.
The DNA-binding domain of p53 (residues 94^312) was polymerase
chain reaction (PCR) ampli¢ed from a human kidney cDNA library
(Clontech) using DNA primers (5P-ACGACGACGTCTCCCATGT-
CATCTTCTGTCCCTTCCCAG-3P and 5P-CGAGAGACGTCTCC-
TCGAGGGTGTTGTTGGGCAGTGCTCGCTTAG-3P). The PCR
product was restriction digested with BsmBI (New England Biolabs),
ligated into a modi¢ed pET15b vector (Novagen, WI, USA) with an
amino-terminal His tag, and expressed in E. coli BL21/DE3 (Nova-
gen). The protein was puri¢ed on an S-protein ion-exchange column
(Bio-Rad) followed by a⁄nity chromatography puri¢cation on a nick-
el-IDA column (Invitrogen). The amino-terminal His tag was left
intact. A uniformly 15N-labelled sample was prepared with minimal
media containing 15NH4Cl as the sole nitrogen source. NMR samples
typically contained 0.1^0.5 mM protein in phosphate-bu¡ered saline
with 10% 2H2O added.
2.2. NMR spectroscopy
NMR spectra were acquired at 298 K on either a Bruker DRX500
or DRX600 spectrometer, equipped with a cryoprobe accessory. Per-
turbations to 13C-labelled Bcl-xL upon binding unlabelled p53 DNA-
binding domain were monitored using either a 13C-heteronuclear sin-
gle-quantum correlation (HSQC) or a 13C-edited nuclear Overhauser
e¡ect spectroscopy (NOESY) spectrum recorded with a mixing time
of 80 ms. Perturbations to the p53 DNA-binding domain upon bind-
ing unlabelled Bcl-xL were monitored with an 15N-HSQC, and the
interpretation of the data was based on previously published assign-
ments [5].
3. Results and discussion
In order to de¢ne the interaction surface for p53 on Bcl-xL,
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we monitored spectral changes in a 13C-HSQC spectrum and
a 13C-edited NOESY spectrum for a sample of uniformly 13C-
labelled Bcl-xL complexed with unlabelled DNA-binding do-
main from p53. Overall, spectra recorded in the presence of
p53 were very similar to those recorded on Bcl-xL alone, sug-
gesting that Bcl-xL does not undergo a major conformation
change upon binding. A representative section of the 13C-
HSQC spectrum for Bcl-xL both alone and in the presence
of the p53 DNA-binding domain is shown in Fig. 1A. As
can be seen, Val-159 and Val-167 are speci¢cally perturbed
upon binding of p53 to Bcl-xL. Additional perturbations ob-
served in this spectrum and in a 13C-edited NOESY spectrum
of Bcl-xL are summarized in Fig. 2A. These residues are lo-
calized to a small region of Bcl-xL including the carboxy-ter-
minus of K1, the loop between K3 and K4, and the loop
between K5 and K6. They are not in the groove formed by
the BH1, BH2, and BH3 regions of the protein that is the
binding site for BH3 peptides, such as those derived from the
anti-apoptotic proteins Bak and Bad, Fig. 2B. In Fig. 2C the
surface of Bcl-xL is shown color coded by atom type. The p53-
binding surface has an acidic character, unlike the hydropho-
bic, BH3 peptide-binding groove.
The binding interface for Bcl-xL on p53 was de¢ned by
adding unlabelled Bcl-xL to 15N-labelled p53 DNA-binding
domain and monitoring the subsequent changes observed in
an 15N-HSQC spectrum. Since assignments for the backbone
amide resonances of the p53 DNA-binding domain have been
reported [5] while those for side chain atoms have not, this
15N-based approach was necessary for p53. As with Bcl-xL,
perturbations to the HSQC spectrum were very speci¢c, as
shown in Fig. 1B, suggesting that the p53 DNA-binding do-
main does not undergo a major conformational change. The
two proteins are in overall fast exchange on the NMR time-
scale as only a single signal is observed for those resonances of
the p53 DNA-binding domain perturbed upon binding to Bcl-
xL and for those of Bcl-xL perturbed upon binding to p53.
This suggests that these proteins associate with a Kd greater
than 1 uM. Fig. 3A shows the residues of the p53 DNA-bind-
ing domain that are signi¢cantly a¡ected by addition of Bcl-
xL. The residues perturbed are localized to the same region
that is used by p53 to contact DNA, Fig. 3B. In particular,
Arg-280, which is perturbed upon binding to Bcl-xL, interacts
directly with the major groove of DNA. A molecular surface
for the p53 DNA-binding domain is shown in Fig. 3C. The
basic character of the interaction site is consistent with its role
in binding DNA and would complement the acidic character
of the Bcl-xL surface shown in Fig. 2C. Several naturally
occurring mutations to the p53 DNA-binding domain have
been identi¢ed which abolish both the transcription-depen-
dent and transcription-independent actions of p53 [2]. These
mutations include R175H, L194F, R273H, and R280K, all of
which lie within or are proximal to the Bcl-xL interface as
de¢ned by the NMR data.
Our results are also consistent with a recently proposed
model of Bcl-xL binding to the p53 DNA-binding domain.
This model was generated using the Global Range Molecular
Matching Program [6]. In this model a loop from the p53
DNA-binding domain comprised of residues 239^248 interacts
with a groove on Bcl-xL formed by K1 and part of K2.
While the residues of the peptide-binding groove of Bcl-xL
were not perturbed upon complexation with p53, part of the
loop between K3 and K4, which is proximal to this groove, is
perturbed by addition of p53, Fig. 2B. Previous studies
showed that K3 moves upon binding of BH3 peptides [4,7].
To test whether p53 can bind to Bcl-xL in the presence of a
BH3 peptide, we added the p53 DNA-binding domain to a
preformed complex of 13C-labelled Bcl-xL with a 25-residue
BH3 peptide from the pro-apoptotic Bad protein. This peptide
binds to Bcl-xL with a dissociation constant of 0.6 nM [7].
Upon subsequent addition of p53 no spectral changes were
observed in the Bcl-xL 13C-HSQC spectrum, suggesting that
the p53 DNA-binding domain does not bind in the presence
of the Bad, BH3 peptide. These data suggest that BH3 peptide
binding to Bcl-xL can in£uence the binding of p53. Peptides
Fig. 1. A: Section of a 13C-HSQC spectrum recorded on 13C-la-
belled Bcl-xL in the absence (black) and presence (red) of a slight
molar excess of unlabelled p53 DNA-binding domain. Resonances
of Bcl-xL perturbed upon binding to the p53 DNA-binding domain
are labelled. B: Section of a 15N-HSQC spectrum recorded on 15N-
labelled p53 DNA-binding domain in the absence (black) and pres-
ence (red) of a slight molar excess of unlabelled Bcl-xL. Resonances
on p53 perturbed upon binding to Bcl-xL are labelled.
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from Bak and Bax which bind much weaker to Bcl-xL, 480
and 13000 nM respectively [8], may not be able to block P53
binding. Indeed, in vivo immunoprecipitation studies on the
binding of p53 to Bcl-xL [2] suggested that overexpression of
the pro-apoptotic Bax protein does not block complex forma-
tion of Bcl-xL with p53. Additional studies need to be done to
investigate the e¡ect of the di¡erent BH3 proteins on the Bcl-
xL/p53 interaction.
4. Conclusions
Recent data have suggested a direct interaction between
Bcl-xL and p53 at the mitochondrial membrane. Using
NMR-based chemical shift mapping, we have investigated
the structural basis of this interaction and have experimentally
de¢ned the relevant interaction surfaces on both proteins.
Furthermore, we have used peptides that mimic the interac-
tion between pro-apoptotic proteins and Bcl-xL to test their
e¡ect on the Bcl-xL/p53 interaction. These new data provide
information at the molecular level on this additional mecha-
nism for the regulation of apoptosis that is initiated by p53.
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